Peptide Atlas — health, wellness & peptide resources
Protocol Reference
TB-500 (thymosin beta-4 fragment)

TB-500 — research context, not a human protocol

Explain what published thymosin beta-4 research covers and why no human protocol for the marketed fragment can be summarised.

Research Use OnlyReviewed September 1, 2026
No established human dosing protocol exists for this compound. What follows describes the research context only — the conditions under which the compound has been studied, usually in animals or in vitro.

Research Context

Source of this information
Published human research concerns full-length thymosin beta-4 in ophthalmic and cardiac settings, not the fragment sold for research use.
Evidence level
Grade D — animal and in-vitro research; early human trials of a different molecule
Population studied
Rodent injury models; small human trials of full-length thymosin beta-4 in corneal disease.
Duration studied
Animal studies of days to weeks.
Route reported
Animal research used subcutaneous and intraperitoneal administration; human ophthalmic research used topical formulations.

Protocol as Reported

  • 01No established human dosing protocol exists for TB-500.
  • 02The fragment marketed as TB-500 is not the molecule used in most published research, so published dosing cannot be mapped onto it.
  • 03Community schedules circulating online do not derive from published protocols.

Adverse Events Reported

  • No systematic human safety data for the fragment.
  • Angiogenic activity raises theoretical oncological questions.

Limitations

  • Molecule mismatch between marketed product and studied protein.
  • No controlled human musculoskeletal outcomes.
  • Prohibited in sport under WADA rules.

Sources

Read the full TB-500 research guide
Educational reference only. Peptide Atlas does not provide medical advice or individualised dosing guidance, and nothing on this page should be used to guide personal use.